Skip to main content
Equibles
BIAF logo

BIAF · bioAffinity Technologies, Inc. · Metrics

Track BIAF — free

Use BIAF with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BIAF.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.06 -0.09 (-1.46%) At close · Oct 2
Rebalance outlook locked
Going-concern doubt — flagged Aug 7, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on our current expected level of operating expenditures, current expected levels of revenue, and the cash and cash equivalents on hand at June 30, 2026, of $2.4 million, management concludes that there is substantial doubt about our ability to continue as a going concern for a period of at least twelve (12) months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements contained in this Quarterly Report.”
View the 10-Q filed Aug 7, 2026
Market Cap
$3.72M
Shares
540,115
Volume · Oct 2 154.64K Avg daily vol (29 sessions) 6.44M

BIAF metrics

49 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.06
Market cap
$3.72M

Price action

20 metrics
Price change (1W)
-23.6%
Price change (30D)
-52.6%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
47.2
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
6.44M
Relative volume
0.0
Average dollar volume
$62.34M

Company

3 metrics
Sector
Healthcare
Industry
Diagnostics & Research
Shares outstanding
540,115

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.6×
reciprocal yield 158.8%
P / book
1.0
reciprocal yield 101.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-408.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2023-04-03

Profitability

9 metrics
Gross margin
—
Operating margin
-209.8%
Trailing 12 months
Net margin
-257.3%
Gross profit (TTM)
$245,289
Operating profit (TTM)
−$12.38M
Net income (TTM)
−$15.19M
Trailing 12 months
Diluted EPS (TTM)
$-3.60
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$24.27

Growth

11 metrics
Revenue growth YoY
+19.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$5.90M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+552.8%
Year over year · more shares
Revenue CAGR (3Y)
-3.7%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-402.9%
Return on assets
-199.3%
Debt / equity
—
Current ratio
1.4
EBITDA (TTM)
−$11.97M
Free cash flow (TTM)
—
Quick ratio
1.4
Interest coverage
-276.1
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$2.43M
Total assets
$7.62M
Total debt
$260,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$11.47M
Capital expenditures (TTM)
$91,988
R&D (TTM)
$1.42M
SG&A (TTM)
$11.35M
Stock compensation (TTM)
$932,532
R&D / revenue
24.0%
Stock compensation / revenue
15.8%

Ownership (13F)

3 metrics
13F filers
22
13F filer change QoQ
+5
Institutional ownership
11.5%

Short interest

3 metrics
Short interest
13.2%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
58 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1712762 CUSIP 09076W406 13F (30d) 1 filings 1 filers Visit website Investor relations